Loading...

Advanced Biologic Adoption Will Expand Global Reach

Published
09 Nov 24
Updated
01 May 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-3.3%
7D
-3.7%

Author's Valuation

€260.0514.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 01 May 25

Fair value Decreased 3.07%

Shared on 23 Apr 25

Fair value Decreased 3.38%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 2.96%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 1.47%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 3.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 8.23%

AnalystConsensusTarget has increased future PE multiple from 53.6x to 62.9x.